2200 - Bankstown - Bankstown-Lidcombe Hospital (WITHDRAWN)2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (WITHDRAWN)

NCT04419649

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) (KER050-MD-201)

NA

2025 - Papatoetoe - Middlemore Hospital

NCT04332822

R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (POLAR-BEAR)

NCT04170283

An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients With B-cell Malignancies (BGB-3111-LTE1)

NCT03850574

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) (TUSCANY)

NCT03666000

Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (PBCAR0191-01)

NCT03537482

A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies (APG2575-001)

NCT03486873

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (3475-587)

NCT03229200

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. (PCYC-1145-LT)

NA

2025 - Papatoetoe - Middlemore Hospital

NCT03175224

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

NCT02889874

NA

A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer (EXPERT)

NCT02468024

JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial

cereblon	23%
PD-1/PD-L1	20%
PD-1	17%
CD38	16%
BCMA	16%
proteasome	13%
Bcl2	11%
CD20	9%
BTK	7%
GPRC5D	6%
CD19	6%
DNA methyltransferase	6%
CS1	6%
EGFR	4%
PD-L1	4%
LAG3	4%
ER	4%
oestrogen axis	4%
Trop2	3%
mTOR	3%
mTORC1	3%
mTORC2	3%
CD79b	3%
CDK4	3%
CDK6	3%
VEGF	3%
CD28	1%
CAR-T-cell generating,CD19	1%
B7H3	1%
ISR	1%
multikinase	1%
PSMA∕STEAP1	1%
XPO1	1%
IDH1	1%
IDH1 R132	1%
KRAS	1%
KRAS G12C	1%
CTLA4	1%
FcRH5	1%
IL-6	1%
PI3K	1%
PI3K alpha	1%
ERBB2	1%
4-1BB	1%
JAK1	1%
JAK2	1%
CCR8	1%
CD47	1%
ROCK2	1%
TGF-beta	1%
HPV-E6	1%
HPV-E7	1%
PARP	1%
MET	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters